http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7034048-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a31d6d5f2e7c2fb8acb6dd14e449a00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate | 2001-05-04^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-04-25^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d7b889a9e11de4435983819df56debe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc2d29b41652eb39de0ba01e5d2e00e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19bee3d1d9fb2b467b40de17c416b334 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8108e2c8d53dd945d319242097c8ac5f |
| publicationDate | 2006-04-25^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7034048-B2 |
| titleOfInvention | Gastrin and cholecystokinin receptor ligands (III) |
| abstract | Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R 5 )—(R 5 being selected from H, Me, Et, Pr, Bn, OH and —CH 2 COOR 6 , wherein R 6 represents H, Me, Et, Pr or Bn), ═CH—, —O— or —S—; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R 1 is H or C 1 to C 15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R 2 is selected from H, Me, Et, Pr and OH, each R 2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R 3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R 3 is independently selected from H, Me, Et and Pr, or two R 3 groups on neighbouring carbon atoms are linked to form a C 3 to C 6 carbocylic ring, or two R 3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R 2 and R 3 on the same carbon atom together represent an ═O group; R 4 is C 1 to C 15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is —CO—NH—SO 2 —Ph, —SO 2 —NH—CO—PH, —CH 2 OH, or a group of the formula —R 7 U, (wherein U is —COOH, tetrazolyl, —CONHOH or —SO 3 H; and R 7 is a bond; C 1 to C 6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; —O—(C 1 to C 3 alkylene)—; —SO 2 NR 8 —CHR 9 —; —CO—NR 8 —CHR 9 —, R 8 and R 9 being independently selected from H and methyl; or —NH—(CO) c —CH 2 , c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described |
| priorityDate | 2000-05-08^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 613 of 613.